Cat. No. 3540
Chemical Name: N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-ox
Biological ActivityHypolipemic pancreatic, gastric and carboxylester lipase inhibitor. Exhibits no activity at phospholipase A2, liver esterase, trypsin and chymotrypsin. Inhibits the thioesterase domain of fatty acid synthase, leading to cell cycle arrest at the G1/S boundary in vitro. Prevents the absorption of approximately one third of fat from food and exhibits progastrokinetic, antiobesity and antihypercholesterolemic activity in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Enc et al (2008) Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. Am.J.Physiol.Gastrointest.Liver Physiol. 296 G482. PMID: 19109408.
Kridel et al (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 64 2070. PMID: 15026345.
Hadvary et al (1991) The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J.Biol.Chem. 266 2021. PMID: 1899234.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Orlistat include:
Caiati et al (2012) Developmental regulation of CB1-mediated spike-time dependent depression at immature mossy fiber-CA3 synapses. Sci Rep 2 285. PMID: 22368777.
Do you know of a great paper that uses Orlistat from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Orlistat, supplier, Fatty, acid, synthases, inhibits, inhibitors, pancreatic, gastric, carboxylester, lipases, Pancreatic, antiobesity, antihypercholesterolemic, antihypercholesterolaemic, activity, Synthases, Esterases, FAS, FASN, Tocris Bioscience, Lipase Inhibitor products